SEARCH

SEARCH BY CITATION

References

  • 1
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 2
    Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817822.
  • 3
    Tsai JF, Jeng JE, Chang WY, Lin ZY, Tsai JH. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1994; 29: 651654.
  • 4
    Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 11011108.
  • 5
    Pramoolsinsap C, Sirikulchayanonta V, Busakorn W, Poovorawan Y, Hirsch P, Theamboonlers A, Lerdverasirikul P. Coinfections with hepatitis G and/or C virus in hepatitis B-related chronic liver disease. Southeast Asian J Trop Med Public Health 1999; 30: 741749.
  • 6
    Sagnelli E, Felaco FM, Filippini P, Scolastico C, Rapicetta M, Stroffolini T, Piccinino F. Multiple hepatitis virus infections in chronic HBsAg carriers in Naples. Arch Virol 1997; 142: 445451.
  • 7
    Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347354.
  • 8
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 9
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332: 14571462.
  • 10
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 14931499.
  • 11
    Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 8387.
  • 12
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 14851492.
  • 13
    Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 13071312.
  • 14
    Liaw YF, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen IS, Chu CM. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997; 17: 449452.
  • 15
    Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C, and delta viruses results in severe chronic liver disease and responds poorly to interferon alpha treatment. J Viral Hepat 1995; 2: 3945.
  • 16
    Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F, Sostegni R, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94: 22462250.
    Direct Link:
  • 17
    Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999; 14: 893898.
  • 18
    Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96: 29732977.
  • 19
    Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 408413.
  • 20
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 21
    Ryff JC. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995; 22 (Suppl 1): 101109.
  • 22
    Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously non-responsive to interferon. A meta-analysis of randomized trials. JAMA 2001; 285: 193199.
  • 23
    Kao JH, Lin HH, Chen PJ, Lai MY, Wang TH, Mizokami M, Chen DS. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996; 31: 224227.
  • 24
    De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 35293536.
  • 25
    Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 2226.
  • 26
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346355.
  • 27
    Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376382.
  • 28
    Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 23812391.
  • 29
    Fang SH, Chiang BL, Wu MH, Iba H, Lai MY, Yang PM, Chen DS, et al. Functional measurement of hepatitis C virus core-specific CD8(+) T-cell responses in the livers or peripheral blood of patients by using autologous peripheral blood mononuclear cells as targets or stimulators. J Clin Microbiol 2001; 39: 38953901.
  • 30
    Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33: 791798.
  • 31
    Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 49: 4609446098.
  • 32
    Lau JYN, Tam RC, Liang TJ, Hong Z. Mecahnism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 10021009.
  • 33
    Bergamini A, Bolacchi F, Cepparulo M, Demin F, Uccella I, Bongiovanni B, Ombres D, et al. Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C. Clin Exp Immunol 2001; 123: 459464.
  • 34
    Manns M, McHutchinson J, Gordon S, Rustgi V, Shiffman M, Reindollar R, Goodman Z, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001: 358:958965.
  • 35
    Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 16231632.
  • 36
    Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001; 8: 118.
  • 37
    National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3S20.
  • 38
    Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 12851291.
  • 39
    Tsai SL, Liaw YF, Yeh CT, Chu CM, Kuo GC. Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995; 21: 908912.
  • 40
    Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 2733.
  • 41
    Dries V, von Both I, Muller M, Gerken G, Schirmacher P, Odenthal M, Bartenschlager R, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology 1999; 29: 223229.
  • 42
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 818823.